#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Forum Diabetologicum / 2019 - 1

Hyperuricemia and kidney

Česká verzia

Authors: Viera Spustová 1;  Andrej Dukát 2
Authors place of work: Ústav farmakológie a klinickej farmakológie – Oddelenie klinickej a experimentálnej farmakoterapie LF SZU v Bratislave 1;  V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava 2
Published in the journal: Forum Diab 2019; 8(1): 26-28

Summary

For a certain time it was known about the relationship between acid uric level and cardiorenal syndrome, but only recently new causalities were shown in the field of pathophysiology and clinics.

Nowadays there is confirmed the role of hyperuricaemia realted renal dysfunction. In this paper, the authors bring the summary of these relationships.

Keywords:

acid uric – cardiorenal syndrome – hyperuricemia

Zdroje
  1. Borghi C, Tykaeski A, Widecka K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J 2018; 25(5): 545–563. Dostupné z DOI: <http://dx.doi.org/10.5603/CJ.2018.0116>.
  2. Giordano C, Karasik O, King-Morris K et al. Uric acid as a Marker of Kidney Disease: Review of the Current Literature. Dis Markers 2015; 2015: 382918: Dostupné z DOI: <http://dx.doi.org/10.1155/2015/382918>.
  3. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47(1): 51–59. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2005.10.006>.
  4. Roncal Jimenez CA, Ishimoto T, Lanaspa MAet al. Fructokinase activity media-tes dehydration-induced renal injury. Kidney Int 2014; 86(2): 294–302. Dostupné z DOI: <http://dx.doi.org/10.1038/ki.2013.492>.
  5. Chonchol M, Shlipak MG, Katz R et al. Relationship of uric acid with progres-sion of kidney disease. Am J Kidney Dis 2007; 50(2): 239–247. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2007.05.013>.
  6. Iseki K, Oshiro S, Tozawa M et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24(6): 691–697.
  7. Weiner DE, Tighiouart H, Elsayed EF et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19(6): 1204–1211. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2007101075>.
  8. Odden MC, Amadu AR, Smit E et al. Uric acid levels, kidney function and cardiovascular mortality in US adults: national health and nutrition examination survey 1988–1994 and 1999–2002. Am J Kidney Dis 2014; 64(4): 550–557. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2014.04.024>.
  9. Weiner DE, Tighiouart H, Elsayed EF et al. The relationship between non-traditional risk factors and outcomes in individuals with stage 3–4 CKD. Am J Kidney Dis 2008; 51(2): 212–223. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2007.10.035>.
  10. Suliman ME, Johnson RJ, García-López E et al. J-shaped mortality rela-tionship for uric acid in CKD. Am J Kidney Dis 2006; 48(5): 761–771. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2006.08.019>.
  11. Goicoechea M1, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5(8): 1388–1393. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.01580210>.
  12. George J, Carr E, Davies J et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114(23): 2508–2516. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.106.651117>.
  13. Ejaz AA, Dass B, Lingegowda V et al. Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery. Int Urol Nephrol 2013; 45(2): 449–458. Dostupné z DOI: <http://dx.doi.org/10.1007/s11255–012–0192–2>.
  14. Høieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65(3): 1041–1049. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1523–1755.2004.00484.x>.
  15. Management of progression and complications of CKD. In: KDIGO 2012 practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3(1): 73–90. Dostupné z DOI: <http://doi:10.1038/kisup.2012.66>.
  16. Lapsia V, Johnson RJ, Dass B et al. Elevated uric acid increases the risk for acute kidney injury. Am J Med 2012; 125(3): 302.e9–e17. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2011.06.021>.
  17. Giordano C, Karasik O, King-Morris K et al. Uric Acid as a Marker of Kidney Disease. Dis Markers 2015; 2015: 382918. Dostupné z DOI: <http://dx.doi.org/10.1155/2015/382918>.
Štítky
Diabetology Endocrinology Internal medicine
Článek Uric acid: pathophysiological implications
Článek Hyperuricemia and cardiovascular diseases
Článek Hyperuricemia and diabetes mellitus
Článek Gout as a new old problem faced by an outpatient care physician
Článek Treatment of hyperuricemia
Článek Treat to target in gouty arthritis
Článok vyšiel v časopise

Forum Diabetologicum

Číslo 1
2019 Číslo 1
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#